Soluble LILRA3 is aberrantly expressed in antiphospholipid syndrome (APS) and is a potential marker of thrombotic APS.
Liu H, Li C, Shi H, Guo Y, Tang Y, Chen C, Zhao Z, Hoy CK, Yalavarthi S, Figueroa-Parra G, Duarte-Garcia A, Zuo Y, Li Z, Knight JS, Guo J.
Liu H, et al. Among authors: zhao z.
Rheumatology (Oxford). 2022 Nov 28;61(12):4962-4974. doi: 10.1093/rheumatology/keac192.
Rheumatology (Oxford). 2022.
PMID: 35325077
Free PMC article.